CL2014000663A1 - Compuestos derivados de 2-oxo-1,2,3,4-tetrahidroquinolina, inhibidores de aldosterona sitasa (cyp11b2 o cyp11b1); proceso para prepararlos; composicion farmaceutica;metodo de tratamiento o profilaxis; y uso para el tratamiento o la profilaxis de una enfermedad renal cronica o fallo cardiaco congestivo, entre otras. - Google Patents
Compuestos derivados de 2-oxo-1,2,3,4-tetrahidroquinolina, inhibidores de aldosterona sitasa (cyp11b2 o cyp11b1); proceso para prepararlos; composicion farmaceutica;metodo de tratamiento o profilaxis; y uso para el tratamiento o la profilaxis de una enfermedad renal cronica o fallo cardiaco congestivo, entre otras.Info
- Publication number
- CL2014000663A1 CL2014000663A1 CL2014000663A CL2014000663A CL2014000663A1 CL 2014000663 A1 CL2014000663 A1 CL 2014000663A1 CL 2014000663 A CL2014000663 A CL 2014000663A CL 2014000663 A CL2014000663 A CL 2014000663A CL 2014000663 A1 CL2014000663 A1 CL 2014000663A1
- Authority
- CL
- Chile
- Prior art keywords
- prophylaxis
- treatment
- sitase
- cyp11b1
- cyp11b2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011080078 | 2011-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000663A1 true CL2014000663A1 (es) | 2014-10-03 |
Family
ID=46963698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000663A CL2014000663A1 (es) | 2011-09-23 | 2014-03-19 | Compuestos derivados de 2-oxo-1,2,3,4-tetrahidroquinolina, inhibidores de aldosterona sitasa (cyp11b2 o cyp11b1); proceso para prepararlos; composicion farmaceutica;metodo de tratamiento o profilaxis; y uso para el tratamiento o la profilaxis de una enfermedad renal cronica o fallo cardiaco congestivo, entre otras. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9353081B2 (es) |
| EP (1) | EP2758388B1 (es) |
| JP (1) | JP6012737B2 (es) |
| KR (1) | KR101723276B1 (es) |
| CN (1) | CN103827101B (es) |
| AR (1) | AR087984A1 (es) |
| AU (1) | AU2012311582B2 (es) |
| BR (1) | BR112014006660B1 (es) |
| CA (1) | CA2845170C (es) |
| CL (1) | CL2014000663A1 (es) |
| CO (1) | CO6870035A2 (es) |
| CR (1) | CR20140089A (es) |
| DK (1) | DK2758388T3 (es) |
| EA (1) | EA035108B1 (es) |
| EC (1) | ECSP14013264A (es) |
| ES (1) | ES2666802T3 (es) |
| HR (1) | HRP20180592T1 (es) |
| HU (1) | HUE038773T2 (es) |
| IL (1) | IL230874A (es) |
| LT (1) | LT2758388T (es) |
| MX (1) | MX366095B (es) |
| MY (1) | MY186165A (es) |
| NO (1) | NO2758388T3 (es) |
| PE (2) | PE20181378A1 (es) |
| PL (1) | PL2758388T3 (es) |
| PT (1) | PT2758388T (es) |
| RS (1) | RS57139B1 (es) |
| SG (1) | SG2014010599A (es) |
| SI (1) | SI2758388T1 (es) |
| TW (1) | TWI576342B (es) |
| UA (1) | UA115972C2 (es) |
| WO (1) | WO2013041591A1 (es) |
| ZA (1) | ZA201401577B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| KR20150001828A (ko) * | 2012-04-17 | 2015-01-06 | 에프. 호프만-라 로슈 아게 | 신규한 페닐-테트라하이드로이소퀴놀린 유도체 |
| CA2891644A1 (en) | 2012-11-19 | 2014-05-22 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines |
| RU2015138961A (ru) * | 2013-03-14 | 2017-04-18 | Ф. Хоффманн-Ля Рош Аг | Производные дигидрохинолин-2-она для применения в качестве ингибиторов альдостеронсинтазы |
| AR096424A1 (es) * | 2013-05-27 | 2015-12-30 | Hoffmann La Roche | Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona |
| CA2902848C (en) * | 2013-05-27 | 2021-09-21 | F. Hoffmann-La Roche Ag | 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds |
| TWI642668B (zh) * | 2013-05-27 | 2018-12-01 | 赫孚孟拉羅股份公司 | 新穎３，４－二氫－２ｈ－異喹啉－１－酮及２，３－二氫異吲哚－１－酮化合物 |
| EP3057941B1 (en) * | 2013-10-17 | 2019-11-20 | F.Hoffmann-La Roche Ag | New phenyl-dihydropyridine derivatives as aldosterone synthase inhibitors |
| WO2015055602A1 (en) * | 2013-10-17 | 2015-04-23 | F. Hoffmann-La Roche Ag | Phenyl-dihydropyridine derivatives as inhibitors of aldosterone synthase |
| CN105593212B (zh) * | 2013-10-17 | 2019-06-04 | 豪夫迈·罗氏有限公司 | 作为醛固酮合酶抑制剂的苯基-二氢吡啶衍生物 |
| JP6622300B2 (ja) * | 2014-10-31 | 2019-12-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規なジヒドロキノリンピラゾリル化合物 |
| CN106660998B (zh) * | 2014-10-31 | 2019-10-25 | 豪夫迈·罗氏有限公司 | 吡唑基-3,4-二氢喹啉-2-酮醛固酮合酶抑制剂 |
| WO2016066662A1 (en) * | 2014-10-31 | 2016-05-06 | F. Hoffmann-La Roche Ag | New dihydroquinoline pyrazolyl compounds as aldosterone synthase inhibitors |
| JP6707084B2 (ja) * | 2014-12-02 | 2020-06-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルドステロンシンターゼ阻害薬 |
| AU2017278446A1 (en) * | 2016-06-10 | 2018-12-20 | Nihon Medi-Physics Co., Ltd. | Non-invasive diagnostic imaging agent for heart disease |
| JP2022530775A (ja) | 2019-05-01 | 2022-07-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | （ｒ）－（２－メチルオキシラン－２－イル）メチル ４－ブロモベンゼンスルホネート |
| BR112023027025A2 (pt) * | 2021-06-24 | 2024-03-12 | Cincor Pharma Inc | Métodos de uso de inibidores da aldosterona sintase |
| WO2023063851A1 (en) * | 2021-10-13 | 2023-04-20 | «Target Medicals» Limited Liability Company | Inhibitors of human aldosterone synthase (cyp11b2) |
| WO2024049885A1 (en) | 2022-09-02 | 2024-03-07 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| WO2024061371A1 (zh) * | 2022-09-23 | 2024-03-28 | 广州威诺森医药科技有限公司 | 一种骈环吡啶类甾体合成酶抑制剂及其制备方法和应用 |
| WO2024109885A1 (zh) * | 2022-11-23 | 2024-05-30 | 上海翰森生物医药科技有限公司 | 吡啶多环类化合物抑制剂、及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4792561A (en) * | 1986-05-29 | 1988-12-20 | Syntex (U.S.A.) Inc. | Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors |
| GB8709448D0 (en) * | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
| US5246944A (en) * | 1991-08-13 | 1993-09-21 | Merck & Co., Inc. | Quinoline angiotensin ii antagonists incorporating a substituted benzyl element |
| WO2005065050A2 (ja) * | 2003-12-25 | 2005-07-21 | Asahi Kasei Pharma Corporation | ２環化合物 |
| ES2446416T3 (es) | 2005-12-09 | 2014-03-07 | Amgen, Inc. | Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
-
2012
- 2012-09-14 US US13/615,901 patent/US9353081B2/en active Active
- 2012-09-20 SI SI201231277T patent/SI2758388T1/en unknown
- 2012-09-20 UA UAA201404207A patent/UA115972C2/uk unknown
- 2012-09-20 PT PT127666287T patent/PT2758388T/pt unknown
- 2012-09-20 HU HUE12766628A patent/HUE038773T2/hu unknown
- 2012-09-20 NO NO12766628A patent/NO2758388T3/no unknown
- 2012-09-20 RS RS20180446A patent/RS57139B1/sr unknown
- 2012-09-20 EP EP12766628.7A patent/EP2758388B1/en active Active
- 2012-09-20 SG SG2014010599A patent/SG2014010599A/en unknown
- 2012-09-20 MX MX2014002624A patent/MX366095B/es active IP Right Grant
- 2012-09-20 BR BR112014006660-4A patent/BR112014006660B1/pt active IP Right Grant
- 2012-09-20 AU AU2012311582A patent/AU2012311582B2/en active Active
- 2012-09-20 KR KR1020147010662A patent/KR101723276B1/ko active IP Right Grant
- 2012-09-20 MY MYPI2014700679A patent/MY186165A/en unknown
- 2012-09-20 CN CN201280045785.3A patent/CN103827101B/zh active Active
- 2012-09-20 PE PE2018001330A patent/PE20181378A1/es unknown
- 2012-09-20 JP JP2014531214A patent/JP6012737B2/ja active Active
- 2012-09-20 WO PCT/EP2012/068472 patent/WO2013041591A1/en active Application Filing
- 2012-09-20 EA EA201490567A patent/EA035108B1/ru not_active IP Right Cessation
- 2012-09-20 PL PL12766628T patent/PL2758388T3/pl unknown
- 2012-09-20 LT LTEP12766628.7T patent/LT2758388T/lt unknown
- 2012-09-20 ES ES12766628.7T patent/ES2666802T3/es active Active
- 2012-09-20 CA CA2845170A patent/CA2845170C/en active Active
- 2012-09-20 DK DK12766628.7T patent/DK2758388T3/en active
- 2012-09-20 PE PE2014000393A patent/PE20141042A1/es active IP Right Grant
- 2012-09-21 AR ARP120103485A patent/AR087984A1/es active IP Right Grant
- 2012-09-21 TW TW101134790A patent/TWI576342B/zh active
-
2014
- 2014-01-31 CO CO14020664A patent/CO6870035A2/es active IP Right Grant
- 2014-02-06 IL IL230874A patent/IL230874A/en active IP Right Grant
- 2014-02-25 CR CR20140089A patent/CR20140089A/es unknown
- 2014-02-28 ZA ZA2014/01577A patent/ZA201401577B/en unknown
- 2014-03-19 CL CL2014000663A patent/CL2014000663A1/es unknown
- 2014-03-21 EC ECSP14013264 patent/ECSP14013264A/es unknown
-
2018
- 2018-04-13 HR HRP20180592TT patent/HRP20180592T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000663A1 (es) | Compuestos derivados de 2-oxo-1,2,3,4-tetrahidroquinolina, inhibidores de aldosterona sitasa (cyp11b2 o cyp11b1); proceso para prepararlos; composicion farmaceutica;metodo de tratamiento o profilaxis; y uso para el tratamiento o la profilaxis de una enfermedad renal cronica o fallo cardiaco congestivo, entre otras. | |
| CL2014001389A1 (es) | Compuestos derivados biciclicos de dihidroisoquinolin-1-ona; proceso de obtencion; composicion faramceutica; y su uso para el tratamiento o la profilaxis de enfermedades renales cronicas, fallo cardiaco congestivo, hipertension, aldosteronismo primario y sindrome de cushing. | |
| BR112014010183A2 (pt) | composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou uma condição de doença mediada por uma fgfr cinase | |
| WO2013052550A3 (en) | Novel imidazole quinoline-based immune system modulators | |
| EA201490418A1 (ru) | Новые макроциклические соединения в качестве ингибиторов фактора xia | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| CO6531458A2 (es) | Nuevos compuestos de espiropiperidina | |
| CL2015001279A1 (es) | Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. | |
| IT1400727B1 (it) | Macchina e metodo per la produzione di filtri composti. | |
| EA201491028A1 (ru) | Способ получения замещенных 5-фтор-1н-пиразолопиридинов | |
| ECSP12011930A (es) | Nuevos compuestos de espiropiperidina | |
| PH12016501462A1 (en) | Neprilysin inhibitors | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| EA201591499A1 (ru) | Замещенные бисфенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза) | |
| CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
| WO2014153203A3 (en) | Alkyl-amine harmine derivatives for promoting bone growth | |
| EP3034082A4 (en) | Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients | |
| CL2015001516A1 (es) | Compuestos derivados de piridopirazinas sustituidas, inhibidores de syk; composicion farmaceutica; metodo para tratar una enfermedad inflamatoria, alergias, enfermedad autoinmune, enfermedad proliferativa celular, entre otras. | |
| WO2016010869A3 (en) | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | |
| CA2881554C (en) | Methods for inhibiting fascin | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| CL2014002845A1 (es) | Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2. | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| IT1401045B1 (it) | Macchina e metodo per la realizzazione di filtri composti. | |
| BR112014001425A2 (pt) | forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo |